Scalper1 News
Payers could be aggressive in trying to drive down prices of new anti-PCSK9 cholesterol drugs, according to a survey of recent comments by RBC Capital Markets. On the other hand, fears of losing money from hepatitis C drugs seem to be fading as U.S. prescriptions are falling off. Analyst Michael Yee rounded up comments from the major health insurers and pharmacy benefit managers on their Q2 earnings calls in a report issued Thursday. After last Scalper1 News
Scalper1 News